

RIBOCICLIB IN METASTASIC BREAST CANCER TREATMENT: FRECUENCY AND ANALYSIS OF DIFFERENTS ADVERSE EFFECTS WHICH REQUIRED INTERVENTION

H. VELAZQUEZ, A. GIL GARCIA, A. ROJAS ALBARRAN, M. GRAGERA GOMEZ, M.D.
ZAMBRANO CROCHE (Spain)

BACKGROUND AND IMPORTANCE

- Ribociclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor with relevant adverse effects
- Target: Breast cancer locally advanced or metastasic HR+/HER2-.



AIM AND OBJECTIVES

- To describe the secondary effects observed, their frequency and how they were faced off.




MATERIAL AND METHODS

- Descriptive, retrospective and observational study.
- Period: January 2013 - September 2023.
- Microsoft Excel[®], Farmatools[®], clinical history.




RESULTS

Toxicity




Treatment modifications



- ✓ Average time to first dose reduction: 83 days.
- ✓ Average time to drug change: 117 days.
- ✓ Average cycles until first event: 2,5.
- ✓ Average cycles until end of study or event: 6,9.

End of study



CONCLUSION AND RELEVANCE

The type and frequency of adverse effects observed were pretty similar to those described in clinical trials (MONALEESA). The dose reductions and drug changes in the treatments of our population were similar too.

